Compare Cassava Sciences Inc (FLNA) vs Lithium Americas Corp (LAC) Price & Performance

FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.

The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.

Lithium Americas (LAC) trades at $2.41, down 5.12% in the last session, reflecting ongoing market pressure despite recent earnings beats. The company shows negative profitability metrics with a -9.56% ROE and -$122.09M net income for 2025, though it maintains strong financing activity with $1.14B in cash flow from financing. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators suggest potential oversold conditions. Recent news highlights construction progress at Thacker Pass as a key development catalyst.

The investment outlook remains speculative with significant execution risk at Thacker Pass offset by analyst optimism (46.67% buy rating) and a $4.00 consensus price target representing 66% upside. Key risks include lithium price volatility, project execution challenges, and sustained negative cash flow from operations. The stock's current valuation at 0.6x book value may attract value investors betting on successful project commercialization.